flex analysis Search Results


automatic blood gas analysis system abl800 flex  (Drott Medizintechnik GmbH)
90
Drott Medizintechnik GmbH automatic blood gas analysis system abl800 flex
Automatic Blood Gas Analysis System Abl800 Flex, supplied by Drott Medizintechnik GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/automatic blood gas analysis system abl800 flex/product/Drott Medizintechnik GmbH
Average 90 stars, based on 1 article reviews
automatic blood gas analysis system abl800 flex - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
g-flex  (Genetic Analysis AS)
90
Genetic Analysis AS g-flex
G Flex, supplied by Genetic Analysis AS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/g-flex/product/Genetic Analysis AS
Average 90 stars, based on 1 article reviews
g-flex - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
waveform analysis software (flex pro7.0  (Weisang GmbH)
90
Weisang GmbH waveform analysis software (flex pro7.0
Waveform Analysis Software (Flex Pro7.0, supplied by Weisang GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/waveform analysis software (flex pro7.0/product/Weisang GmbH
Average 90 stars, based on 1 article reviews
waveform analysis software (flex pro7.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
adaboost analysis nextera flex for enrichment library prep method  (Nextera AS)
90
Nextera AS adaboost analysis nextera flex for enrichment library prep method
Adaboost Analysis Nextera Flex For Enrichment Library Prep Method, supplied by Nextera AS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adaboost analysis nextera flex for enrichment library prep method/product/Nextera AS
Average 90 stars, based on 1 article reviews
adaboost analysis nextera flex for enrichment library prep method - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
ncounter flex analysis system  (LakePharma)
90
LakePharma ncounter flex analysis system
WTX-124 treatment increases CD8 + T-cell activation and Treg fragility in B16-F10 Tumors. B16-F10 tumors were implanted and allowed to grow to an average volume of 100–150 mm 3 before mice were randomized into treatment groups. Mice were dosed twice a week with either PBS or with various doses of WTX-124. Some mice also received PD-1 blockade in addition to WTX-124 treatment. A, Tumor volume was measured over time. Data from individual mice (dashed lines) are depicted with the group average presented in bold. B, Tumor volume on day 12. C–I, Tumors from mice treated with either the vehicle or WTX-124 (200 μg/dose) were harvested 24 hours after the second dose. C, RNA from each tumor was isolated and subjected to immune profiling with the NanoString <t>nCounter</t> PanCancer Mouse Immune Profiling panel. Heatmap of transcripts with statistically significant differences in expression between the two treatments. Transcripts were excluded from the heatmap if they had average normalized counts below 50. Each lane represents an individual animal. D–I, TILs were restimulated with PMA/Ionomycin and examined for effector cytokine production and proliferation. D and E, The frequency of tumor-infiltrating tetramer-positive CD8 + T cells producing granzyme B or expressing Ki67. The tetramer used in these experiments was the same tetramer from . F and G, The frequency of tumor-infiltrating NK cells producing granzyme B or expressing Ki67. H and I, The frequency of tumor-infiltrating CD4 + Tregs producing IFNγ or TNF. In plots comparing only two groups, P values are derived from t tests ( * , P < 0.05; ** , P < 0.01; *** , P < 0.001; **** , P < 0.0001). In plots comparing multiple groups, P values are derived from a one-way ANOVA followed by Dunnett multiple comparisons comparing each sample with the vehicle control ( * , P < 0.05; *** , P < 0.001; **** , P < 0.0001).
Ncounter Flex Analysis System, supplied by LakePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ncounter flex analysis system/product/LakePharma
Average 90 stars, based on 1 article reviews
ncounter flex analysis system - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
clinical autoanalyzer siemens dimension vista system flex analysis system  (Siemens AG)
90
Siemens AG clinical autoanalyzer siemens dimension vista system flex analysis system
WTX-124 treatment increases CD8 + T-cell activation and Treg fragility in B16-F10 Tumors. B16-F10 tumors were implanted and allowed to grow to an average volume of 100–150 mm 3 before mice were randomized into treatment groups. Mice were dosed twice a week with either PBS or with various doses of WTX-124. Some mice also received PD-1 blockade in addition to WTX-124 treatment. A, Tumor volume was measured over time. Data from individual mice (dashed lines) are depicted with the group average presented in bold. B, Tumor volume on day 12. C–I, Tumors from mice treated with either the vehicle or WTX-124 (200 μg/dose) were harvested 24 hours after the second dose. C, RNA from each tumor was isolated and subjected to immune profiling with the NanoString <t>nCounter</t> PanCancer Mouse Immune Profiling panel. Heatmap of transcripts with statistically significant differences in expression between the two treatments. Transcripts were excluded from the heatmap if they had average normalized counts below 50. Each lane represents an individual animal. D–I, TILs were restimulated with PMA/Ionomycin and examined for effector cytokine production and proliferation. D and E, The frequency of tumor-infiltrating tetramer-positive CD8 + T cells producing granzyme B or expressing Ki67. The tetramer used in these experiments was the same tetramer from . F and G, The frequency of tumor-infiltrating NK cells producing granzyme B or expressing Ki67. H and I, The frequency of tumor-infiltrating CD4 + Tregs producing IFNγ or TNF. In plots comparing only two groups, P values are derived from t tests ( * , P < 0.05; ** , P < 0.01; *** , P < 0.001; **** , P < 0.0001). In plots comparing multiple groups, P values are derived from a one-way ANOVA followed by Dunnett multiple comparisons comparing each sample with the vehicle control ( * , P < 0.05; *** , P < 0.001; **** , P < 0.0001).
Clinical Autoanalyzer Siemens Dimension Vista System Flex Analysis System, supplied by Siemens AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/clinical autoanalyzer siemens dimension vista system flex analysis system/product/Siemens AG
Average 90 stars, based on 1 article reviews
clinical autoanalyzer siemens dimension vista system flex analysis system - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
cba flex set cytokine kit  (Becton Dickinson)
90
Becton Dickinson cba flex set cytokine kit
WTX-124 treatment increases CD8 + T-cell activation and Treg fragility in B16-F10 Tumors. B16-F10 tumors were implanted and allowed to grow to an average volume of 100–150 mm 3 before mice were randomized into treatment groups. Mice were dosed twice a week with either PBS or with various doses of WTX-124. Some mice also received PD-1 blockade in addition to WTX-124 treatment. A, Tumor volume was measured over time. Data from individual mice (dashed lines) are depicted with the group average presented in bold. B, Tumor volume on day 12. C–I, Tumors from mice treated with either the vehicle or WTX-124 (200 μg/dose) were harvested 24 hours after the second dose. C, RNA from each tumor was isolated and subjected to immune profiling with the NanoString <t>nCounter</t> PanCancer Mouse Immune Profiling panel. Heatmap of transcripts with statistically significant differences in expression between the two treatments. Transcripts were excluded from the heatmap if they had average normalized counts below 50. Each lane represents an individual animal. D–I, TILs were restimulated with PMA/Ionomycin and examined for effector cytokine production and proliferation. D and E, The frequency of tumor-infiltrating tetramer-positive CD8 + T cells producing granzyme B or expressing Ki67. The tetramer used in these experiments was the same tetramer from . F and G, The frequency of tumor-infiltrating NK cells producing granzyme B or expressing Ki67. H and I, The frequency of tumor-infiltrating CD4 + Tregs producing IFNγ or TNF. In plots comparing only two groups, P values are derived from t tests ( * , P < 0.05; ** , P < 0.01; *** , P < 0.001; **** , P < 0.0001). In plots comparing multiple groups, P values are derived from a one-way ANOVA followed by Dunnett multiple comparisons comparing each sample with the vehicle control ( * , P < 0.05; *** , P < 0.001; **** , P < 0.0001).
Cba Flex Set Cytokine Kit, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cba flex set cytokine kit/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cba flex set cytokine kit - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
clinical autoanalyser siemens dimension vista system flex analysis system  (Siemens AG)
90
Siemens AG clinical autoanalyser siemens dimension vista system flex analysis system
WTX-124 treatment increases CD8 + T-cell activation and Treg fragility in B16-F10 Tumors. B16-F10 tumors were implanted and allowed to grow to an average volume of 100–150 mm 3 before mice were randomized into treatment groups. Mice were dosed twice a week with either PBS or with various doses of WTX-124. Some mice also received PD-1 blockade in addition to WTX-124 treatment. A, Tumor volume was measured over time. Data from individual mice (dashed lines) are depicted with the group average presented in bold. B, Tumor volume on day 12. C–I, Tumors from mice treated with either the vehicle or WTX-124 (200 μg/dose) were harvested 24 hours after the second dose. C, RNA from each tumor was isolated and subjected to immune profiling with the NanoString <t>nCounter</t> PanCancer Mouse Immune Profiling panel. Heatmap of transcripts with statistically significant differences in expression between the two treatments. Transcripts were excluded from the heatmap if they had average normalized counts below 50. Each lane represents an individual animal. D–I, TILs were restimulated with PMA/Ionomycin and examined for effector cytokine production and proliferation. D and E, The frequency of tumor-infiltrating tetramer-positive CD8 + T cells producing granzyme B or expressing Ki67. The tetramer used in these experiments was the same tetramer from . F and G, The frequency of tumor-infiltrating NK cells producing granzyme B or expressing Ki67. H and I, The frequency of tumor-infiltrating CD4 + Tregs producing IFNγ or TNF. In plots comparing only two groups, P values are derived from t tests ( * , P < 0.05; ** , P < 0.01; *** , P < 0.001; **** , P < 0.0001). In plots comparing multiple groups, P values are derived from a one-way ANOVA followed by Dunnett multiple comparisons comparing each sample with the vehicle control ( * , P < 0.05; *** , P < 0.001; **** , P < 0.0001).
Clinical Autoanalyser Siemens Dimension Vista System Flex Analysis System, supplied by Siemens AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/clinical autoanalyser siemens dimension vista system flex analysis system/product/Siemens AG
Average 90 stars, based on 1 article reviews
clinical autoanalyser siemens dimension vista system flex analysis system - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
cytoflex flow cytometers  (Danaher Inc)
99
Danaher Inc cytoflex flow cytometers
WTX-124 treatment increases CD8 + T-cell activation and Treg fragility in B16-F10 Tumors. B16-F10 tumors were implanted and allowed to grow to an average volume of 100–150 mm 3 before mice were randomized into treatment groups. Mice were dosed twice a week with either PBS or with various doses of WTX-124. Some mice also received PD-1 blockade in addition to WTX-124 treatment. A, Tumor volume was measured over time. Data from individual mice (dashed lines) are depicted with the group average presented in bold. B, Tumor volume on day 12. C–I, Tumors from mice treated with either the vehicle or WTX-124 (200 μg/dose) were harvested 24 hours after the second dose. C, RNA from each tumor was isolated and subjected to immune profiling with the NanoString <t>nCounter</t> PanCancer Mouse Immune Profiling panel. Heatmap of transcripts with statistically significant differences in expression between the two treatments. Transcripts were excluded from the heatmap if they had average normalized counts below 50. Each lane represents an individual animal. D–I, TILs were restimulated with PMA/Ionomycin and examined for effector cytokine production and proliferation. D and E, The frequency of tumor-infiltrating tetramer-positive CD8 + T cells producing granzyme B or expressing Ki67. The tetramer used in these experiments was the same tetramer from . F and G, The frequency of tumor-infiltrating NK cells producing granzyme B or expressing Ki67. H and I, The frequency of tumor-infiltrating CD4 + Tregs producing IFNγ or TNF. In plots comparing only two groups, P values are derived from t tests ( * , P < 0.05; ** , P < 0.01; *** , P < 0.001; **** , P < 0.0001). In plots comparing multiple groups, P values are derived from a one-way ANOVA followed by Dunnett multiple comparisons comparing each sample with the vehicle control ( * , P < 0.05; *** , P < 0.001; **** , P < 0.0001).
Cytoflex Flow Cytometers, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cytoflex flow cytometers/product/Danaher Inc
Average 99 stars, based on 1 article reviews
cytoflex flow cytometers - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
specs-flex xps system  (SPECS Surface Nano Analysis GmbH)
90
SPECS Surface Nano Analysis GmbH specs-flex xps system
WTX-124 treatment increases CD8 + T-cell activation and Treg fragility in B16-F10 Tumors. B16-F10 tumors were implanted and allowed to grow to an average volume of 100–150 mm 3 before mice were randomized into treatment groups. Mice were dosed twice a week with either PBS or with various doses of WTX-124. Some mice also received PD-1 blockade in addition to WTX-124 treatment. A, Tumor volume was measured over time. Data from individual mice (dashed lines) are depicted with the group average presented in bold. B, Tumor volume on day 12. C–I, Tumors from mice treated with either the vehicle or WTX-124 (200 μg/dose) were harvested 24 hours after the second dose. C, RNA from each tumor was isolated and subjected to immune profiling with the NanoString <t>nCounter</t> PanCancer Mouse Immune Profiling panel. Heatmap of transcripts with statistically significant differences in expression between the two treatments. Transcripts were excluded from the heatmap if they had average normalized counts below 50. Each lane represents an individual animal. D–I, TILs were restimulated with PMA/Ionomycin and examined for effector cytokine production and proliferation. D and E, The frequency of tumor-infiltrating tetramer-positive CD8 + T cells producing granzyme B or expressing Ki67. The tetramer used in these experiments was the same tetramer from . F and G, The frequency of tumor-infiltrating NK cells producing granzyme B or expressing Ki67. H and I, The frequency of tumor-infiltrating CD4 + Tregs producing IFNγ or TNF. In plots comparing only two groups, P values are derived from t tests ( * , P < 0.05; ** , P < 0.01; *** , P < 0.001; **** , P < 0.0001). In plots comparing multiple groups, P values are derived from a one-way ANOVA followed by Dunnett multiple comparisons comparing each sample with the vehicle control ( * , P < 0.05; *** , P < 0.001; **** , P < 0.0001).
Specs Flex Xps System, supplied by SPECS Surface Nano Analysis GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/specs-flex xps system/product/SPECS Surface Nano Analysis GmbH
Average 90 stars, based on 1 article reviews
specs-flex xps system - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
flex-center endothelial analysis method  (Konan Medical USA)
90
Konan Medical USA flex-center endothelial analysis method
WTX-124 treatment increases CD8 + T-cell activation and Treg fragility in B16-F10 Tumors. B16-F10 tumors were implanted and allowed to grow to an average volume of 100–150 mm 3 before mice were randomized into treatment groups. Mice were dosed twice a week with either PBS or with various doses of WTX-124. Some mice also received PD-1 blockade in addition to WTX-124 treatment. A, Tumor volume was measured over time. Data from individual mice (dashed lines) are depicted with the group average presented in bold. B, Tumor volume on day 12. C–I, Tumors from mice treated with either the vehicle or WTX-124 (200 μg/dose) were harvested 24 hours after the second dose. C, RNA from each tumor was isolated and subjected to immune profiling with the NanoString <t>nCounter</t> PanCancer Mouse Immune Profiling panel. Heatmap of transcripts with statistically significant differences in expression between the two treatments. Transcripts were excluded from the heatmap if they had average normalized counts below 50. Each lane represents an individual animal. D–I, TILs were restimulated with PMA/Ionomycin and examined for effector cytokine production and proliferation. D and E, The frequency of tumor-infiltrating tetramer-positive CD8 + T cells producing granzyme B or expressing Ki67. The tetramer used in these experiments was the same tetramer from . F and G, The frequency of tumor-infiltrating NK cells producing granzyme B or expressing Ki67. H and I, The frequency of tumor-infiltrating CD4 + Tregs producing IFNγ or TNF. In plots comparing only two groups, P values are derived from t tests ( * , P < 0.05; ** , P < 0.01; *** , P < 0.001; **** , P < 0.0001). In plots comparing multiple groups, P values are derived from a one-way ANOVA followed by Dunnett multiple comparisons comparing each sample with the vehicle control ( * , P < 0.05; *** , P < 0.001; **** , P < 0.0001).
Flex Center Endothelial Analysis Method, supplied by Konan Medical USA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flex-center endothelial analysis method/product/Konan Medical USA
Average 90 stars, based on 1 article reviews
flex-center endothelial analysis method - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
finite element analysis (fea) code pz flex  (Weidlinger Associates Inc)
90
Weidlinger Associates Inc finite element analysis (fea) code pz flex
WTX-124 treatment increases CD8 + T-cell activation and Treg fragility in B16-F10 Tumors. B16-F10 tumors were implanted and allowed to grow to an average volume of 100–150 mm 3 before mice were randomized into treatment groups. Mice were dosed twice a week with either PBS or with various doses of WTX-124. Some mice also received PD-1 blockade in addition to WTX-124 treatment. A, Tumor volume was measured over time. Data from individual mice (dashed lines) are depicted with the group average presented in bold. B, Tumor volume on day 12. C–I, Tumors from mice treated with either the vehicle or WTX-124 (200 μg/dose) were harvested 24 hours after the second dose. C, RNA from each tumor was isolated and subjected to immune profiling with the NanoString <t>nCounter</t> PanCancer Mouse Immune Profiling panel. Heatmap of transcripts with statistically significant differences in expression between the two treatments. Transcripts were excluded from the heatmap if they had average normalized counts below 50. Each lane represents an individual animal. D–I, TILs were restimulated with PMA/Ionomycin and examined for effector cytokine production and proliferation. D and E, The frequency of tumor-infiltrating tetramer-positive CD8 + T cells producing granzyme B or expressing Ki67. The tetramer used in these experiments was the same tetramer from . F and G, The frequency of tumor-infiltrating NK cells producing granzyme B or expressing Ki67. H and I, The frequency of tumor-infiltrating CD4 + Tregs producing IFNγ or TNF. In plots comparing only two groups, P values are derived from t tests ( * , P < 0.05; ** , P < 0.01; *** , P < 0.001; **** , P < 0.0001). In plots comparing multiple groups, P values are derived from a one-way ANOVA followed by Dunnett multiple comparisons comparing each sample with the vehicle control ( * , P < 0.05; *** , P < 0.001; **** , P < 0.0001).
Finite Element Analysis (Fea) Code Pz Flex, supplied by Weidlinger Associates Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/finite element analysis (fea) code pz flex/product/Weidlinger Associates Inc
Average 90 stars, based on 1 article reviews
finite element analysis (fea) code pz flex - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


WTX-124 treatment increases CD8 + T-cell activation and Treg fragility in B16-F10 Tumors. B16-F10 tumors were implanted and allowed to grow to an average volume of 100–150 mm 3 before mice were randomized into treatment groups. Mice were dosed twice a week with either PBS or with various doses of WTX-124. Some mice also received PD-1 blockade in addition to WTX-124 treatment. A, Tumor volume was measured over time. Data from individual mice (dashed lines) are depicted with the group average presented in bold. B, Tumor volume on day 12. C–I, Tumors from mice treated with either the vehicle or WTX-124 (200 μg/dose) were harvested 24 hours after the second dose. C, RNA from each tumor was isolated and subjected to immune profiling with the NanoString nCounter PanCancer Mouse Immune Profiling panel. Heatmap of transcripts with statistically significant differences in expression between the two treatments. Transcripts were excluded from the heatmap if they had average normalized counts below 50. Each lane represents an individual animal. D–I, TILs were restimulated with PMA/Ionomycin and examined for effector cytokine production and proliferation. D and E, The frequency of tumor-infiltrating tetramer-positive CD8 + T cells producing granzyme B or expressing Ki67. The tetramer used in these experiments was the same tetramer from . F and G, The frequency of tumor-infiltrating NK cells producing granzyme B or expressing Ki67. H and I, The frequency of tumor-infiltrating CD4 + Tregs producing IFNγ or TNF. In plots comparing only two groups, P values are derived from t tests ( * , P < 0.05; ** , P < 0.01; *** , P < 0.001; **** , P < 0.0001). In plots comparing multiple groups, P values are derived from a one-way ANOVA followed by Dunnett multiple comparisons comparing each sample with the vehicle control ( * , P < 0.05; *** , P < 0.001; **** , P < 0.0001).

Journal: Cancer Immunology Research

Article Title: Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression

doi: 10.1158/2326-6066.CIR-21-0831

Figure Lengend Snippet: WTX-124 treatment increases CD8 + T-cell activation and Treg fragility in B16-F10 Tumors. B16-F10 tumors were implanted and allowed to grow to an average volume of 100–150 mm 3 before mice were randomized into treatment groups. Mice were dosed twice a week with either PBS or with various doses of WTX-124. Some mice also received PD-1 blockade in addition to WTX-124 treatment. A, Tumor volume was measured over time. Data from individual mice (dashed lines) are depicted with the group average presented in bold. B, Tumor volume on day 12. C–I, Tumors from mice treated with either the vehicle or WTX-124 (200 μg/dose) were harvested 24 hours after the second dose. C, RNA from each tumor was isolated and subjected to immune profiling with the NanoString nCounter PanCancer Mouse Immune Profiling panel. Heatmap of transcripts with statistically significant differences in expression between the two treatments. Transcripts were excluded from the heatmap if they had average normalized counts below 50. Each lane represents an individual animal. D–I, TILs were restimulated with PMA/Ionomycin and examined for effector cytokine production and proliferation. D and E, The frequency of tumor-infiltrating tetramer-positive CD8 + T cells producing granzyme B or expressing Ki67. The tetramer used in these experiments was the same tetramer from . F and G, The frequency of tumor-infiltrating NK cells producing granzyme B or expressing Ki67. H and I, The frequency of tumor-infiltrating CD4 + Tregs producing IFNγ or TNF. In plots comparing only two groups, P values are derived from t tests ( * , P < 0.05; ** , P < 0.01; *** , P < 0.001; **** , P < 0.0001). In plots comparing multiple groups, P values are derived from a one-way ANOVA followed by Dunnett multiple comparisons comparing each sample with the vehicle control ( * , P < 0.05; *** , P < 0.001; **** , P < 0.0001).

Article Snippet: RNA samples were shipped to LakePharma and analyzed using the nCounter Mouse PanCancer Immune Profiling Codeset Panel with the nCounter FLEX analysis system.

Techniques: Activation Assay, Isolation, Expressing, Derivative Assay, Control